{"id":1937,"date":"2025-12-03T13:35:25","date_gmt":"2025-12-03T13:35:25","guid":{"rendered":"https:\/\/www.chromacon.com\/?post_type=application&p=1937"},"modified":"2026-05-08T11:08:05","modified_gmt":"2026-05-08T09:08:05","slug":"mabs","status":"publish","type":"application","link":"https:\/\/www.chromacon.com\/en\/applications\/mabs\/","title":{"rendered":"mAbs & Antibody Variants"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

\n MONOCLONAL ANTIBODIES <\/p>\n \n

\n CaptureSMB\u00ae \u2014 Continuous Capture Chromatography for mAbs<\/strong>\n <\/h1>\n \n
\n

Twin-column Protein A capture for mAb manufacturing. Load Protein A to its true capacity \u2014 and keep it there, cycle after cycle. Validated from lab to GMP production scale by Bristol Myers Squibb at 100\u00d7 scale-up: 2.5\u00d7<\/strong> Productivity | 92%<\/strong> Resin utilisation (vs. 67% batch) | 50%<\/strong> less buffer | \u226594%<\/strong> Yield (equivalent to batch)<\/p>\n

 <\/p>\n

Source: Angelo et al., BioProcess International 2018; M\u00fcller-Sp\u00e4th et al., Biotechnol. Bioeng. 2019 (Bristol Myers Squibb)<\/em><\/strong><\/p>\n <\/div>\n <\/div>\n\n

\n
\n Talk to Our mAb Specialists<\/span><\/a><\/span> <\/div>\n
\n Download the mAb Application Note<\/span><\/a><\/span> <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n
\n
\n \"\" <\/div>\n\n \n
\n
\n Talk to Our mAb Specialists<\/span><\/a><\/span> <\/div>\n
\n Download the mAb Application Note<\/span><\/a><\/span> <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n
\n \n
\n
\n
\n

\n The Protein A Capture Bottleneck <\/h2>\n \n
\n

Monoclonal antibodies dominate the biopharmaceutical market \u2014 with 100+ approved products, a rapidly growing biosimilar wave, and expanding next-generation formats (bispecifics, ADCs, Fc-fusion proteins). Downstream purification must keep pace.<\/p>\n

The Protein A affinity capture step is the cornerstone of mAb downstream processing \u2014 but conventional batch chromatography is inherently inefficient. Columns are loaded conservatively to only 50\u201370% of the resin’s dynamic binding capacity<\/strong>, leaving expensive Protein A resin underutilized. Long sequential cycle times (load \u2192 wash \u2192 elute \u2192 regenerate \u2192 re-equilibrate) create idle column time, limiting throughput and inflating facility footprint.<\/p>\n

With cell culture titers now routinely exceeding 5\u201315 g\/L and perfusion bioreactors demanding continuous feed processing, the batch capture step is the rate-limiting bottleneck in modern mAb manufacturing.<\/p>\n <\/div>\n \n <\/div>\n\n

\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/section>\n\n
\n \n
\n
\n
\n

\n The Solution: CaptureSMB\u00ae with AutomAb\u00ae for mAb Capture <\/h2>\n \n
\n

CaptureSMB\u00ae is an optimized twin-column periodic countercurrent (PCC) process for continuous Protein A capture of monoclonal antibodies and antibody variants. Two identical columns operate in coordinated interconnected and parallel phases \u2014 maximizing resin utilization by safely loading well beyond the breakthrough point, while the second column captures any product that breaks through. The result: 2.5\u00d7 higher productivity (BMS-demonstrated), 92% resin utilization (vs. 67% batch), and 50% buffer savings<\/strong> compared to batch.<\/p>\n

AutomAb\u00ae dynamic process control uses in-line UV sensors at each column outlet to monitor the breakthrough curve in real-time, automatically adjusting the interconnected loading duration to compensate for feed titer variability, column aging, and batch-to-batch variation \u2014 ensuring robust, unattended 24\/7 continuous capture.<\/p>\n

\n

Same resin. Same buffers. Superior performance.<\/strong> CaptureSMB works with all major Protein A resins \u2014 MabSelect SuRe, MabSelect PrismA, Amsphere, and others \u2014 and uses your existing wash, elution, regeneration, and CIP buffers unchanged. Your current batch conditions are the starting point; CaptureSMB\u00ae is developed from there. Only two columns required \u2014 the simplest PCC configuration available.<\/p>\n<\/blockquote>\n <\/div>\n \n Learn About CaptureSMB\u00ae with AutomAb\u00ae<\/span><\/a><\/span> <\/div>\n\n

\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/div><\/section>\n\n\n

Proven Results: CaptureSMB\u00ae vs. Batch – Protein A Capture – mAb<\/h2>\n\n\n\n
\n
\n
\n \n \n
\n \n

\n 2.5\u00d7 <\/h2>\n \n

\n Productivity Increase
\r\n8.4 \u2192 26.5 g\/L\/h
\r\n <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 92% <\/h2>\n \n

\n Resin Utilization
\r\nvs. 67% batch <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 50% \u2193 <\/h2>\n \n

\n Buffer Reduction
\r\n0.73 \u2192 0.34 L\/g <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n<\/div>\n\n\n\n

\n
\n
\n \n \n
\n \n

\n \u226594% <\/h2>\n \n

\n Yield Maintained
\r\nConsistent at both scales <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 24\/7 <\/h2>\n \n

\n Continuous Operation
\r\nPerfusion-ready <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 100\u00d7 <\/h2>\n \n

\n Scale-Up Validated
\r\nCUBE \u2192 TWIN (BMS) <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n<\/div>\n\n\n

\n \n
\n \n